[1] | Potts M. (1994). The urgent need for a vaginal microbicide in the prevention of HIV transmission. Am J Public Health. 84: (6): 890-1. |
|
[2] | Thurman AR, Clark MR & DoncelGF. (2011). Multipurpose Prevention Technologies: Biomedical Tools to Prevent HIV-1, HSV-2, and Unintended Pregnancies. Infect Dis Obstet Gynecol. 2011:1-10. |
|
[3] | Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, MansoorLE,Kharsany ABM, Sibeko S,1 Mlisana KP, Omar, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L & Taylor D. (2010). Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 329: (5996):1168-74. |
|
[4] | Ashish J Lokesh K, Bhavana K, Monika S, Aastha P, Vikas V, Vikas S, Vishal S, Tara R & Vishnu L. S. (2013). Combining a synthetic spermicide with a natural trichomonacide for safe, prophylactic contraception. Hum. Reprod. |
|
[5] | Keller MJ, Carpenter CA, Lo Y, Einstein MH, Liu C, Fredricks DN & Herold BC. (2012). Phase I Randomized Safety Study of Twice Daily Dosing of Acidform Vaginal Gel: Candidate Antimicrobial Contraceptive. PLOS One 7:10:e46901. |
|
[6] | Elias CJ & Heise LL (1994). Challenges for the development of female-controlled vaginal microbicides. AIDS. 8: (1):1-9. |
|
[7] | Uckun FM, D’Cruz OJ. Prophylactic contraceptives for HIV/AIDS. Human Reprod Update, 1999, 5: (5): 506-14. |
|
[8] | D’Cruz OJ & (2004). Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Design. 10: (3): 315-36. |
|
[9] | Obiero J, Maureen, Ndung’u, M. Waititu KK, Mulei I, Farah IO& Peter G. Mwethera UniPron is A Fully Effective Non-hormonal Reversible Contraceptive in Baboon Model (Papio Anubis). (2008). J Reprod & Contracep. 19: (2): 107-18. |
|
[10] | Mburu N, Obiero JA, Waititu K, Mwaura BN, Orawo JO, Farah IO & Mwethera PG. (2009). Safety Studies of a Recently Developed Microbicidal Contraceptive Gel (UniPron) in Female Baboons (Papio anubis). Afri J Reprod Health. 13: (4):95-104. |
|
[11] | McGowan I, Gomez K, Bruder K, Febo I, Chen BA, Richardson BA, Husnik M, Livant E, Price C & Jacobson C. (2011). Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS. 25(8):1057-64. |
|
[12] | Sokal DC, Karim QA, Sibeko S, Yende-Zuma N, Mansoor LE, Baxter C, Grobler A, Frolich J, Kharsany AB, Miya N, Mlisana K, Maarshalk S & Karim SS. (2013). Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. Antivir Ther. 18: (3):301-10. |
|
[13] | Grammen C\, Ariën KK, Venkatraj M, Joossens J, Van der Veken P, Heeres J, Lewi PJ, Haenen S, Augustyns K, Vanham G, Augustijns P & Brouwers J. (2014). Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1. Antiviral Res. 101: 113-21. |
|
[14] | Wilkinson D, Tholandi M, Ramjee G, & Rutherford GW. (2002). Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis 2002; 2: 613-7. |
|
[15] | Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiègne-Traoré V, Uaheowitchai C, Karim SS, Mâsse B, Perriëns J, Laga M. (2002). Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 360: (9338): 971-7. |
|
[16] | Obiero J, Mwethera PG &Wiysonge CS. (2012). Topical microbicides for prevention of sexually transmitted infections (2012). Cochrane Database System Rev. Issue 6. Art. No.: CD007961. |
|
[17] | Obiero J, Mwethera PG, Hussey GD, Wiysonge CS. (2012). Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infectious Diseases. 12: 289. |
|
[18] | Obiero JA, Kunyera R, waititu KK, Mulei I, Farah IO, Linge K, Jaoko W & Mwethera PG. (2013). A Comparative Study of Smugel and KY Jelly Vaginal Lubricating Gels. J Reprod Contracep. 24: (2):76-87. |
|
[19] | Nyachieo A, Kiulia NM, Arimi MM, et al. Vaginal histological changes of the baboon during the normal menstrual cycle and pregnancy. East Afr Med J, 2009, 86(4):166-72. |
|
[20] | Sobel JD. (2000). Bacterial vaginosis. Annu Rev Med. 2000. 51:349-356. |
|
[21] | Ursell LK, Gunawardana M, Chang S, Mullen M, Moss JA, Herold BC, Keller MJ, McDonald D, González A, Knight R & Baum MM. (2013). Comparison of the vaginal microbial communities in women with recurrent genital HSV receiving acyclovir intravaginal rings. Antiviral Res. 19: (102C): 87-94. |
|
[22] | Rose WA II, McGowin CL, Spagnuolo RA, Eaves-Pyles TD, Popov VL & Pyles RB. (2012). Commensal Bacteria Modulate Innate Immune Responses of Vaginal Epithelial Cell Multilayer Cultures. PLoS One. 7: (3): e32728. |
|
[23] | Rivera, AJ, Stumpf RM, Wilson B, Leigh S & Salyers AA. (2010). Baboon vaginal microbiota: an overlooked aspect of primate physiology. Am J Primatol. 72: (6): 467-74. |
|
[24] | Fichorova RN, Yamamoto HS, Delaney ML, Onderdonk AB & Doncel GF. (2011). Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action. mBio. 2: (6):e00168-11. |
|
[25] | Stafford MK, Ward W, Flanagan A, Rosenstein IJ Taylor-Robinson D, Smith JR, Weber J & Kitchen VS. (1998). Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol. 17: 327-31. |
|
[26] | Richardson BA, Martin HL Jr, Stevens CE, Hillier SL, Mwatha AK, Chohan BH, Nyange PM, Mandaliya K, Ndinya-Achola J & Kreiss JK. (1998). Use of nonoxynol-9 and changes in vaginal lactobacilli. J Infect Dis. 178: (2): 441-5. |
|
[27] | Veazey RS. (2008). Microbicide Safety/Efficacy studies in animals -macaques and small animal models. Curr Opin HIV AIDS. 3: (5). |
|
[28] | Rosenberg ZF & Devlin B. (2012). Future strategies in microbicide development. Best Pract Res Clin Obstet Gynaecol. 26: (4): 503-13. |
|